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Effects of Conjugated Linoleic Acid on Myogenic
and Inflammatory Responses in a Human Primary Muscle
and Tumor Coculture Model
Amy E. Larsen and Timothy C. Crowe
School of Exercise and Nutrition Sciences, Deakin University, Burwood, Victoria, Australia
The antiproliferative and anti-inflammatory properties of con-
jugated linoleic acid (CLA) make it a potentially novel treatment in
chronic inflammatory muscle wasting disease, particularly cancer
cachexia. Human primary muscle cells were grown in coculture
with MIA PaCa-2 pancreatic tumor cells and exposed to varying
concentrations of c9,t11 and t10,c12 CLA. Expression of myogenic
(Myf5, MyoD, myogenin, and myostatin) and inflammatory genes
(CCL-2, COX-2, IL-8, and TNF-α) were measured by real-time
PCR. The t10,c12 CLA isomer, but not the c9,t11 isomer, signifi-
cantly decreased MIA PaCa-2 proliferation by between 15% and
19%. There was a marked decrease in muscle MyoD and myogenin
expression (78% and 62%, respectively), but no change in either
Myf5 or myostatin, in myotubes grown in coculture with MIA
PaCa-2 cells. CLA had limited influence on these responses. A sim-
ilar pattern of myogenic gene expression changes was observed
in myotubes treated with TNF-α alone. Several-fold significant in-
creases in CCL-2, COX-2, IL-8, and TNF-α expression in myotubes
were observed with MIA PaCa-2 coculture. The c9,t11 CLA iso-
mer significantly decreased basal expression of TNF-α in myotubes
and could ameliorate its tumor-induced rise. The study provides
insight into the anti-inflammatory and antiproliferative actions of
CLA and its application as a therapeutic agent in inflammatory
disease states.
INTRODUCTION
Muscle wasting is the most important phenotypic feature of
cancer cachexia and the principal cause of morbidity and mor-
tality in cancer patients (1). Skeletal muscle is a highly adaptable
tissue that responds to physiological challenges by changes in
size and metabolism with changes in muscle growth and devel-
opment under the strict control of myogenic regulatory factors
(MRFs) MyoD, Myf5, myogenin, and myostatin (2). MRFs
are critical for the determination and terminal differentiation
of skeletal muscle and together play an important role in the
expression of the overall muscle phenotype (3).
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Currently, therapeutic interventions in cancer cachexia aimed
at increasing muscle mass and weight are of limited benefit (4).
Cancer cachexia is regarded as a chronic inflammatory condi-
tion, with current strategies for managing it focusing on the use
of novel anti-inflammatory agents (5). In recent times conju-
gated linoleic acid (CLA), a group of positional and geometric
isomers of linoleic acid found naturally in meat and dairy prod-
ucts derived from ruminant animals, have shown promise in both
reducing inflammation and as an anticarcinogenic agent (6).
CLA is formed during a process of bacterial biohydrogena-
tion of linoleic acid in the rumen. Initially the cis-9,trans-11
(c9,t11) isomer of CLA is produced in the rumen of cattle
through microbial biohydrogenation of linoleic and linolenic
acids. Thereafter, c9,t11 CLA may be directly absorbed (7) or
biohydrenated to trans-11,cis-12 (t11,c12) CLA (vaccenic acid),
the predominant trans monounsaturated fatty acid in milk (8).
Although 28 different isomers of CLA exist, c9,t11 accounts for
more than 90% of the CLA intake in the human diet (5).
Health benefits of CLA have been attributed to the two main
isomer forms of c9,t11 and t10,c12, which are the predominant
active biologically forms that exhibit numerous physiological
properties (9,10). A large number of animal studies, and in
more recent times human intervention studies, have attributed
health-related effects of CLA involving anticarcinogenic, an-
tiatherogenic, antidiabetogenic, and immunomodulatory actions
(11–13). Many in vitro studies have demonstrated that CLA in-
hibits, in a dose- and time-dependent manner, the proliferation of
several human tumor cell lines from breast, lung, prostate, skin,
and colon (9,14). It has been observed that t10,c12 CLA is the
most potent isomer in inhibiting the proliferation of colon cancer
cells (15,16); however, in other experimental models, the c9,t11
isomer has been found to exhibit greater antiproliferative effects
in both colorectal and prostate cancer cell lines (17). Recently, it
has been suggested that the anticarcinogenic properties of CLA
stem from its anti-inflammatory properties by negatively regu-
lating the expression of some proinflammatory genes such as
tumor necrosis factor-α (TNF-α), interleukin(IL)-1β (IL-1 β),
and IL-6 (18). Furthermore, it has also been reported that CLA
may elicit beneficial effects in cachexia. Studies have shown
that CLA has the capacity to preserve muscle mass in tumor
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bearing and endotoxin challenged cachectic animals, decreas-
ing skeletal muscle wasting and reducing the catabolic effects
of TNF-α, suggesting overall protective properties of CLA in
cachexia (19–23).
Due to its antiproliferative and potential anti-inflammatory
properties, CLA could be a novel dietary supplement for patients
suffering from muscle wasting in chronic inflammatory-related
disease, particularly cancer cachexia. Few studies have exam-
ined the antitumorogenic and anti-inflammatory effects of CLA
in a physiologic relevant human model; thus, the aims of the
present study were to investigate 1) dose-response and time-
dependent effects of individual CLA isomers on proliferation
ability of two human tumor cell lines, a colon and a pancreatic
tumor line; and 2) use a novel human primary muscle and tu-
mor coculture model to ascertain the effects of tumor secretion
products and individual CLA isomers on myogenic and inflam-
matory mediators of gene expression in an in vitro model of
cancer cachexia.
MATERIALS AND METHODS
Primary Muscle Cell Culture
Primary muscle cells were obtained from healthy adult male
volunteers and cultured as previously described (24).
Tumor Cell Culture
Murine colon adenocarcinoma tumor cells (MAC13) were
obtained from the laboratory of Professor J. A. Double (Uni-
versity of Bradford, UK) and were maintained in RPMI 1640
medium with L-glutamine (Gibco BRL, Life Technologies,
Rockville, MD) supplemented with 10% FBS (Gibco, Carlsbad,
CA) and 0.5% penicillin-streptomycin (Gibco) in a humidified
atmosphere with 5% CO2 at 37◦C. Cells were passaged once
they achieved 80% confluency. The MIA PaCa-2 cell line,
established from the tumor tissue of the pancreas from a
65-yr-old Caucasian male, was obtained from the American
Type Culture Collection (ATCC, Manassas, VA). Cells were
maintained in Dulbecco’s modified eagles medium (DMEM;
Gibco, Carlsbad, CA) with 4 mmol/l L-glutamine, 4.5 g/L
glucose, and 3.7 g/l sodium bicarbonate and supplemented with
10% FBS, 2.5% horse serum, and 0.5% penicillin/streptomycin
in a humidified atmosphere with 5% CO2 at 37◦C.
Experimental Design: Coculture Experiments
Primary human muscle cells were seeded at a density of ap-
proximately 6 × 105 cells per well into the lower chambers
of MULTIWELLTM 6-well tissue culture plates (Falcon Lakes,
NJ) and grown to approximately 80% confluency. Four days af-
ter addition of differentiation medium (α-MEM supplemented
with 2% horse serum, 0.5% Fungizone, and 0.5% penicillin-
streptomycin), cell culture inserts (Labware, Carlsbad, NJ) with
a pore size of 1.0 µm were seeded at a density of approximately
6 × 105 cells per well with the MIA PaCa-2 tumor cell line
and inserted into the upper chambers of the 6-well tissue cul-
ture plates. CLA (individual c9,t11 and t10,c12 CLA isoforms;
Adelab Scientific, Thebarton, South Australia) stock solutions
(500 mmol/) were further diluted in ethanol at a working con-
centration of 25 µmol/l. Individual CLA isomers were added to
the differentiated myotubes for 96 h at Day 4 after addition of
the differentiation medium. Cells in the upper and lower cham-
bers were maintained in differentiation media with or without
CLA, which was refreshed every 48 h. Control primary mus-
cle cells were maintained in differentiation medium containing
1% ethanol as a vehicle control in the absence of MIA PaCa-2-
cells. Following 4 days of coculture with the MIA PaCa-2 cells,
skeletal muscle cells were washed twice with 1 × PBS and lysed
with TRI reagent. The homogenate was collected and frozen at
–80◦C for later extraction and analysis.
Cell Proliferation and Viability Assessment
The colorimetric 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-
tetrazolium bromide (MTT; Sigma-Aldrich, St. Louis, MO) as-
say was used to quantify cell viability/proliferation. MAC13 and
MIA PaCa-2 cells were seeded and maintained in the appropriate
RPMI 1640 and DMEM medium and grown to subconfluency
in 96-well microplates before treatment. The medium was then
removed and replaced by medium containing different concen-
trations of the CLA isomers ranging from 0 to 150 µmol/l.
After 72 h of treatment, the medium was removed, and MTT
was added to each well (20 ml of 5 mg/ml in PBS solution), and
plates were incubated for 4 h at 37◦C. Absorbance was mea-
sured at 550 nm. Medium containing 1% ethanol was used as a
blank.
RNA Extraction
Total RNA was extracted from cell culture using TRI reagent
(Sigma-Aldrich, St Louis, MO). Cells were washed twice with
PBS, and TRI reagent added to lyse the cells. The homogenate
was collected and 200 µl per 1 ml of chloroform added to the
sample. After 10 min incubation and centrifugation to facili-
tate the separation of phases, the aqueous phase was removed
and transferred to a fresh tube. RNA was precipitated with an
equal volume of isopropanol and refrigerated overnight to aid
in precipitation of the RNA. The following day, samples were
centrifuged to obtain an RNA pellet. The pellet was then washed
with 75% ethanol and resuspended in 5 µl nuclease-free water
and stored at –80◦C in small aliquots.
RNA Quantification and Reverse Transcription
Prior to reverse transcription, the diluted RNA was heated to
65◦C for 10 min and then quenched on ice for 5 min. RNA, 1 µg,
was reverse transcribed to synthesize first-strand cDNA using
the AMV reverse transcriptase kit (A3500; Promega, Madison,
WI). The RNA was added to a master mix containing a final
concentration of 5 mmol/l MgCl2, 10 mmol/l Tris-HCl (pH
8.8), 50 mmol/l KCl, 1% Triton X-100, 1 mmol/l of each dNTP,
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TABLE 1
Real-time primer detailsa
Gene Concentration (µmol/l) GenBank Accession No. Primer Sequences
Myf5 4 NM 005593 Forward: 5′-TTCTACGACGGCTCCTGCATA 3′
Reverse: 5′-CCACTCGCGGCACAAACT 3′
MyoD 4 NM 002478 Forward: 5′-CCGCCTGAGCAAAGTAAATGA 3′
Reverse: 5′-GCAACCGCTGGTTTGGATT 3′
Myogenin 2 NM 002479 Forward: 5′-GGTGCCCAGCGAATGC 3′
Reverse: 5′-TGATGCTGTCCACGATGGA 3′
Myostatin 2 NM 005259 Forward: 5′-CCAGGAGAAGATGGGCTGAA 3′
Reverse: 5′-CAAGACCAAAATCCCTTCTGGAT 3′
CCL-2 2 S69738 Forward: 5′-CGCCTCCAGCATGAAAGTCT-3′
Reverse: 5′-GGAATGAAGGTGGCTGCTATG-3′
COX-2 2 NM 000963 Forward: 5′-GAAGCCTGTGATACTTTCTGTACT-3′
Reverse: 5′-GAATCATTCACCAGGCAAATTG-3′
IL-8 2 NM 000584 Forward: 5′-CTGGCCGTGGCTCTCTTG-3′
Reverse: 5′-TTAGCACTCCTTGGCAAAACTG-3′
TNF-α 2 NM 000594 Forward: 5′-GGAGAAGGGTGACCGACTCA-3′
Reverse: 5′-TGCCCAGACTCGGCAAAG-3′
Cyclophilin 2 NM 021130 Forward: 5′-CATCTGCACTGCCAAGACTGA-3′
Reverse: 5′-TTCATGCTTCTTTCACTTTG C-3′
aAbbreviations are as follows: CCL-2, chemokine (C-C motif) ligand 2; COX-2, cyclooxygenase-2; IL-8, interleukin-8; TNF-α, tumor necrosis
factor-alpha.
20 U Recombinant Rnasin Ribonuclease Inhibitor (40 U/µl),
and 1 µg oligo (dT)15 Primer per 1 µg RNA. Following the ad-
dition of 15 U AMV Reverse Transcriptase (20 U/µl; Promega,
Madison, WI), the mixture was incubated at 42◦C for 60 min be-
fore the reaction was terminated by incubation at 99◦C for 5 min
followed by 5 min at 4◦C using the PCR Express Thermal Cycler
(Hybaid, Middlesex, UK). The cDNA was stored at –20◦C for
subsequent analysis. A reverse transcription (RT) negative was
obtained by not adding any RNA to an aliquot of the RT mix.
Primer Design
To perform PCR, specific primers (Table 1) were designed
for all genes using Primer Express Version 2 software (Ap-
plied Biosystems, Foster City, CA) on sequences obtained from
GenBank at <http://www.ncbi.nlm.nih.gov>. Where possible,
primers were designed spanning intron-exon boundaries to pre-
vent amplification of the target region from any contaminat-
ing DNA. Exon information was obtained from the Ensembl
Genome Database at http://www.ensembl.org/index.html.
Quantification of mRNA expression was performed (in trip-
licate) by real-time PCR using the ABI PRISM 5700 sequence
detection system (Applied Biosystems, Foster City, CA) (25).
Real-Time PCR Analysis
PCR reactions were performed in a volume of 20 µl
containing 18 µl SYBR Green 1 Buffer (Applied Biosys-
tems, Foster City, CA), forward and reverse primers, and
cDNA template (diluted 1:40). All samples were run in
triplicate. Real-time PCR was run for 1 cycle (50◦C, 2
min; 95◦C, 10 min) followed by 40 cycles (95◦C, 15 s;
60◦C, 60 s), and fluorescence was measured after each of the
repetitive cycles. A melting point dissociation curve generated
by the instrument was used to confirm that only a single prod-
uct was amplified. Fluorescent emission data were captured,
and mRNA levels were quantitated using the critical threshold
(CT) value. To compensate for variations in input RNA amounts
and efficiency of reverse transcription, cyclophilin mRNA was
quantitated and results were normalized to these values.
Statistical Analysis
Changes in tumor cell proliferation in the presence of dif-
ferent doses or time of addition of CLA were determined by
1-way ANOVA with Dunnett’s post hoc testing. Experiments
examining the effects of tumor cells and CLA on gene expres-
sion in differentiated myoblasts were analyzed by general linear
modeling with univariance testing and post hoc unpaired t-tests
where appropriate. Statistical analysis was conducted using the
Statistical Package for the Social Sciences (SPSS version 14).
All data are presented as means ± SEM of separate cell lines,
each grown individually in triplicate. Statistical significance was
considered at P < 0.05.
RESULTS
Effect of CLA on Tumor Cell Proliferation
The dose-response effects of individual CLA isomers
(c9,t11 CLA and t10,c12 CLA) on the proliferation of MIA
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FIG. 1. Effect of c9,t11 CLA () and t10,c12 CLA () on A: MIA
PaCa-2 and B: MAC13 tumor cell proliferation as measured by MTT as-
say. Cells were incubated in the presence of increasing doses of CLA (0 to
150 µmol/l) for 72 h. Values are expressed as means ± SEM, n = 12. *P <
0.01 compared to untreated cells.
PaCa-2 (pancreatic) and MAC13 (colon) tumor cells as mea-
sured by MTT assay is shown in Fig. 1. At concentrations rang-
ing from 25 to 150 µmol/l, the t10,c12 isomer of CLA was able
to significantly decrease both pancreatic and colon cancer cell
proliferation by between 15% and 19% after 72 h incubation. In
contrast, the c9,t11 isomer of CLA had no significant effect on
MIA PaCa-2 or MAC13 cell proliferation. Time-dependent ef-
fects were also evident after 72 h, with a significant decrease in
proliferation of the MIA PaCa-2 cell line by 37% after exposure
to 100 µmol/l of the t10,c12 CLA isomer (Fig. 2).
Myogenic and Inflammatory Responses in a Primary
Muscle-Tumor Coculture Model
The influence of tumor secretion products as well as CLA
on myogenic gene expression in a human primary muscle and
tumor coculture model was studied (Fig. 3). Primary muscle
FIG. 2. Time dependent effects of c9,t11 CLA and t10,c12 CLA on prolif-
eration of MIA PaCa-2 cells as measured by MTT assay. Cells were exposed
to individual CLA isomers (100 µmol/l) for () 24 h and () 72 h. Values are
expressed as means ± SEM, n = 24. *P < 0.01 compared to untreated cells.
cells were differentiated for 4 days and then exposed to hu-
man pancreatic tumor cell (MIA PaCa-2) in a coculture system.
Muscle cells were then incubated in the presence of tumor alone,
with or without c9,t11 or t10,c12 CLA isomers (25 µmol/l) for
96 h. Although there was a marked decrease in muscle MyoD
expression in muscle cells when grown in the presence of MIA
PaCa-2 cells alone or combined with CLA isomers, this failed
to reach statistical significance. Myogenin expression signifi-
cantly decreased with exposure to MIA PaCa-2 cells and was
similarly reduced in the presence of the individual c9,t11 and
t10,c12 CLA isomers, although there was no evidence of an ad-
ditive effect of CLA and tumor on this response. Neither Myf5
nor myostatin expression were significantly altered in response
to MIA PaCa-2 or CLA exposure.
Table 2 shows the percentage change in myogenic genes in
human muscle cells when exposed to MIA PaCa-2 cells in a
coculture system for 4 days against the effects of incubation of
the muscle cells with TNF-α (10 ng/ml) for a similar period of
time. A similar pattern of myogenic gene expression changes
was observed in myotubes following exposure to either MIA
PaCa-2 or TNF-α.
TABLE 2
Changes in myogenic gene expression in primary human
myoblasts in coculture with MIA PaCa-2 tumor cells or
TNF-αa
Change in Myogenic Gene Expressionb
MIA PaCa-2 TNF-α
MyoD −78% −68%
Myogenin −62% −63%
Myf5 +54% +227%
Myostatin +26% +24%
aAbbreviation is as follows: TNF-α, tumor necrosis factor-alpha.
bValues are expressed as percentage change of 3 different human
cell lines grown in triplicate relative to primary human muscle cells in
the absence of TNF-α or MIA PaCa-2.
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FIG. 3. Effect of individual c9,t11 and t10,c12 CLA isomers on myogenic gene expression of A: MyoD, B: myogenin, C: Myf5, and D: myostatin in a human
primary muscle and tumor (MIA PaCa-2) coculture model. Primary muscle cells were incubated in the presence or absence of MIA PaCa-2 cells for 96 h, 4 days
postdifferentiation. CLA (25 µmol/l) was added to the coculture system for 96 h. Values are means ± SEM of 3 different human cell lines grown in triplicate.
*P < 0.05 compared to untreated cells.
A potential anti-inflammatory influence of CLA in a primary
muscle and tumor coculture model was examined by measur-
ing expression of specific inflammatory genes (Fig. 4). Primary
muscle cells were differentiated for 4 days and then exposed to
MIA PaCa-2 tumor cells in a coculture system. Cells were incu-
bated in the presence of tumor alone, with or without c9,t11 or
t10,c12 CLA isomers (25 µmol/l), for 96 h. Several-fold signif-
icant increases in CCL-2, COX-2, IL-8, and TNF-α expression
in myotubes were observed with MIA PaCa-2 co-culture. In the
presence of either CLA isomer alone, CCL-2, COX-2, and IL-8
expression were unaltered; however, basal TNF-α expression
was observed to significantly decrease in the presence of the
c9,t11 CLA isomer. Addition of either isomer of CLA could
significantly attenuate the tumor-induced rise in TNF-α gene
expression.
DISCUSSION
Muscle wasting is the most important phenotypic feature of
cancer cachexia and the principal cause of morbidity and mor-
tality in cancer patients. Currently, therapeutic interventions in
cancer cachexia aimed at increasing muscle and weight are of
limited benefit; however, novel dietary fatty acids such as CLA
may have utility in ameliorating some of the perturbations of
this condition owing to CLA’s anti-inflammatory, antitumoro-
genic, and antiproliferative properties (11,26). The study pre-
sented herein examined the dose-response and time-dependent
effects of both the c9,t11 and the t10,c12 isomers of CLA on
MIA PaCa-2 and MAC13 tumor cells and found a significant
antiproliferative effect of the t10,c12 isomer, but not the c9,t11
isomer, at physiologic concentrations. This supports previous
research showing the trans isomer’s potential antiproliferative
properties on human colon (27,28), prostate (29), and mammary
cancer cell proliferation in vitro (30).
The mechanism behind the differential effects of the two
CLA isomers on in vitro tumor proliferation remains unclear.
It is postulated that the c9,t11 CLA isomer mediates pre-
dominant anti-inflammatory effects by suppressing arachidonic
metabolism mediating eicosanoid production or acting as a
PPAR ligand, suppressing lipid transcription (31). However,
information about CLA effects on gene expression of major en-
zymes involved in arachidonic acid metabolism to eicosanoids
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FIG. 4. Effect of individual c9,t11 CLA and t10,c12 CLA isomers on inflammatory gene expression of A: CCL-2, B: IL-8, C:) COX-2 and D: TNF-α in
a human primary muscle and tumor coculture model. Primary muscle cells were incubated in the presence or absence of MIA PaCa-2 cells for 96 h, 4 days
postdifferentiation. CLA (25 µmol/l) was added to the coculture system for 96 h. Values are means ± SEM of 3 different human cell lines grown in triplicate.
*P < 0.05 compared to untreated cells.
in cancer cells and tissues is extremely limited. The t10,c12
CLA isomer has, however, been shown to elicit the greatest an-
tiproliferative effect of the two isomers, and its action is likely
through modulation of genes involved in apoptosis such as Bcl-
2 and Bax, and cell cycle control (29,32). Another proposed
mechanism for the distinct actions of c9,t11 and t10,c12 iso-
mers may also be attributed to their differential metabolism
within the body. It has been observed that although CLA under-
goes similar transformations as linoleic acid, it is preferentially
incorporated into neutral lipids. Furthermore metabolism of the
individual CLA isomers differ, whereby c9,t11 and t10,c12 are
metabolized at a different rate in the peroxisomes, whereas the
shortened metabolite t10,c12 is formed at a much higher propor-
tion than that of c9,t11 (33,34). Previously, it has been demon-
strated that TNF-α plays a detrimental role on myogenesis in
human skeletal muscle and that CLA is unable to ameliorate
these antimyogenic effects (35). To further characterize the role
of CLA in inflammatory muscle states, a novel human primary
muscle coculture model was used to delineate the specific tu-
mor and CLA isomer effects on myogenic gene expression. It
was observed that exposure to secretion products of MIA PaCa-
2 tumor cells caused a marked decrease in MyoD expression
and significantly decreased myogenin expression in myotubes.
Neither isomer of CLA though could significantly alter these
aforementioned responses. Although there was a trend for in-
creased Myf5 expression in the presence of MIA PaCa-2 cells,
no significant effects were observed on myostatin expression
upon exposure to either MIA PaCa-2 or CLA.
Interestingly, the overall changes in the expression of the 4
myogenic genes (MyoD, myogenin, Myf5, and myostatin) were
similar to that seen when myotubes were exposed to TNF-α
alone. As TNF-α has been shown in previous studies to sig-
nificantly decrease the expression of specific myogenic genes
involved in skeletal muscle growth and development (35–37), it
can be postulated that both TNF-α and other tumor-derived fac-
tors (TDFs) are acting through similar underlying mechanisms
through suppression of specific MRFs. It is well known that
both TNF-α and TDFs are capable of upregulating the ubiquitin
proteasome pathway (UPP) resulting in an increase in protein
degradation and a muscle wasting phenotype (38–40). It is also
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well recognized that TNF-α is able to induce other inflamma-
tory mediators that play a role in the pathogenesis of cachexia
with both TNF-α and proteolysis-inducing factor (PIF) able to
increase the activation of nuclear factor-κB (NF-κB) transcrip-
tion of proinflammatory cytokines (40–42). These observations
make it tempting to speculate that the tumor itself may be di-
rectly secreting TNF-α or other factors that are capable of induc-
ing TNF-α release, as the effects on myogenic gene expression
in both models of inflammation are similar.
It was interesting to observe that neither CLA isomer was able
to modulate the effects of TDFs on myogenic gene expression,
specifically MyoD and myogenin, in the tumor-muscle cocul-
ture system. Similar to these aforementioned findings, previous
research has found that CLA exhibits limited benefit on coun-
teracting the effects of TNF-α exposure on MyoD and myo-
genin expression in human myotubes and in fact was observed
to suppress their expression as well as exhibiting negative ef-
fects on the structural genes creatine kinase and myosin heavy
chain IIX (MHC IIX) (35). These results suggest that CLA’s
actions may actually be antimyogenic; however, in contrast to
the aforementioned observations, CLA has been shown to have
some favorable effects in skeletal muscle. Previous research has
shown that CLA could diminish myostatin expression in pri-
mary muscle cells (35), suggesting that CLA may be acting
to promote muscle growth and development, which may partly
explain its previously observed favorable effects on body com-
position (43). This present study provides additional evidence
of CLA’s divergent actions on myogenesis in skeletal muscle;
however, the specific mechanisms behind these effects are yet
to be fully elucidated.
In addition to the effects of CLA on myogenesis, the
present study also aimed to delineate the effects of CLA and
tumor coculture on the expression of specific inflammatory
mediators. Inflammation plays an important role in the de-
velopment of cachexia where specific proinflammatory cy-
tokines, chemokines (CCL-2, IL-8), and TDFs result in a
poor outcome for the patient. Other regulatory enzymes such
as cyclooxygenases 1 and 2 (COX-1, COX-2) also play an
important role in AA metabolism and the formation of inflam-
matory mediators such as prostanoids (44). TNF-α, IL-8, COX-
2, and CCL-2 expression were significantly upregulated within
myotubes in response to incubation with Mia PaCa-2 cells, sug-
gesting that secretion products from the cancer cells can induce
an inflammatory response in the surrounding muscle cells. The
increase in TNF-α expression in myotubes is a positive find-
ing, as tumor cells have been shown to secrete cytokines, which
cause an infiltration of certain inflammatory mediators into the
tumor microenvironment triggering inflammatory signaling, an-
giogenesis, and tumor-host communication (45). Tumor cells
also possess the ability to cause direct catabolism of skeletal
muscle through secretion of PIF and lipid mobilizing factor
(LMF), which act directly on skeletal muscle, promoting fat
and protein breakdown (46). In the coculture model developed
in the present study, it can be postulated that tumor-derived me-
diators may possess the capacity to act as cofactors with host- or
tumor-derived cytokines, augmenting the overall inflammatory
response.
Addition of the individual CLA isomers to the tumor-muscle
coculture system was unable to attenuate the expression of CCL-
2, IL-8, and COX-2. Interestingly, though, the c9,t11 CLA iso-
mer was observed to significantly decrease basal expression of
TNF-α in myotubes and exhibited evidence of amelioration of
the increase in TNF-α transcription in the presence of MIA
PaCa-2 cells, providing further evidence to support the anti-
inflammatory role/properties for c9,t11 CLA. Conflicting evi-
dence exists of the specific effects of the CLA isomers on inflam-
matory mediators both in vivo and in vitro. Previous studies have
shown differential effects of CLA on mediators of the inflam-
matory response in diverse models of inflammation (18,31,47).
In the current study, CLA was found to exhibit no beneficial
effects on CCL-2, IL-8, and COX-2 expression in a coculture
model and supports findings from studies in which CLA has
been observed to have no effect on cytokine-induced MCP-1 or
IL-8 expression and overall chemokine release in human im-
mune cells (48). Furthermore, studies have shown no effect of
CLA on eicosanoid formation or cytokine release (TNF-α, IL-
6) in vivo (14,48), overall immune function in both human and
rodent models (49,50), and COX-2 mRNA and protein levels
in pancreatic tumor cells (29). Conversely, other studies have
provided evidence that CLA decreases transcription of TNF-
α, TNF-α induced expression of COX-2, and TNF-α induced
eicosanoid release in human smooth muscle and colonic epithe-
lial cell lines (31,47). Furthermore, CLA has also been found
to exhibit anti-inflammatory properties inhibiting both TNF-α
and COX-2 expression in macrophages and overall prostanoid
release (23,44). The anti-inflammatory role of CLA in these
aforementioned studies is predominantly attributed to the c9,t11
isomer, which has been well documented in the literature as the
main isomer to possess specific anti-inflammatory properties
(23). The current study further supports this role, as the c9,t11
isomer was able to decrease basal levels of TNF-α expression
and was also observed to exhibit a “blunting” effect on TNF-α
expression upon exposure to MIA Paca-2.
In summary, this is the first study to report specific tumor
effects on myogenic and inflammatory gene expression in an
in vitro human primary coculture model. Furthermore, the ob-
served myogenic gene changes in coculture were similar to that
observed when myotubes are treated with TNF-α, indicating
a common inflammatory pathway that can alter muscle cell
growth and differentiation properties. Of the individual CLA
isomers, the t10,c12 isomer was observed to significantly in-
hibit tumor growth but was unable to attenuate the expression
of inflammatory factors that play a major role in the inflam-
matory response. Furthermore the proposed anti-inflammatory
c9,t11 CLA isomer was observed to significantly reduce basal
TNF-α expression and ameliorate MIA PaCa-2 transcriptional
effects, supporting previous evidence for this isomer acting as
an anti-inflammatory agent. Host and tumor factors play an
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important role in the upregulation of the inflammatory response
and the overall wasting phenotype observed in patients with
cachexia. The study presented here provides a further insight
into the potential actions of the anti-inflammatory and antipro-
liferative fatty acid CLA and its application as a therapeutic
agent in inflammatory disease states.
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